Austin | Jotup

AYRO to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021 and Provide Corporate Update

Retrieved on:

Monday, November 8, 2021

Compliance, Form 10-K, Organization, Technology, Goal, Research, Forward-looking statement, Intention, Annual report, Conference, Company, GLOBE, Solution, SEC, Nasdaq, Risk, Animal, Risk management

AUSTIN, Nov. 08, 2021 (GLOBE NEWSWIRE) -- AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro distribution, micro mobility, and last-mile delivery, announces that it will now report third quarter 2021 financial results on Monday, November 15, 2021, instead of the originally announced earnings release date of Thursday, November 11, 2021.

Key Points:

Also, the previously announced earnings conference call originally scheduled for Thursday, November 11, 2021 at 8:30 a.m.
ET will be replaced by a business update call to be held by the end of 2021.
I look forward to updating investors on our business and strategic vision.
Texas-based AYRO, Inc. designs and produces all-electric, purpose-built vehicles that are powered by technology and usable by anyone.

Carlos Morales Joins Ultra-Low Power Semiconductor Technology Leader Ambiq As Vice President of AI

Retrieved on:

Monday, November 8, 2021

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ambiq announces that Carlos Morales has joined the company as Vice President of Artificial Intelligence (AI).

Key Points:

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ambiq announces that Carlos Morales has joined the company as Vice President of Artificial Intelligence (AI).
Carlos Morales has over 30 years of research and development experience spanning silicon to cloud.
Most recently, he headed and led a company-wide AI strategy and business development initiatives with a global AI Software Teamat Intel for five years.
Ambiqs patented Subthreshold Power Optimized Technology (SPOT) platform has revolutionized IoT endpoint devices by enabling a massive increase in compute power at unprecedented energy levels.

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

Retrieved on:

Monday, November 8, 2021

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled dry powder version of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA) (NCT #04576325). This study assessed the safety and tolerability of patients with mild to moderate asthma, a population at high risk of developing IPA, in two cohorts of eight patients. Initial data from the study suggests that TFF VORI is well tolerated in asthma patients, supporting the Company’s progress to Phase 2 study in IPA patients.

Key Points:

This study assessed the safety and tolerability of patients with mild to moderate asthma, a population at high risk of developing IPA, in two cohorts of eight patients.
Initial data from the study suggests that TFF VORI is well tolerated in asthma patients, supporting the Companys progress to Phase 2 study in IPA patients.
By assessing asthma patients in this Phase 1b reactive airway, we hope to demonstrate that our Voriconazole Inhalation Powder would allow for treatment of patients with IPA that have hyperreactive airway disease comorbidities.
This Phase 1b reactive airway study is a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and induction of bronchospasm of Voriconazole Inhalation Powder (VIP) in 16 patients with mild to moderate asthma patients.

TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021

Retrieved on:

Monday, November 8, 2021

Jefferies, TFF, Absorption, Pharmacokinetics, Conference, Company, Solubility, Toy, Generic drug, Pharmaceutical industry

For more information about the Jefferies London Healthcare Conference, please visit the Jefferies conference website .

Key Points:

For more information about the Jefferies London Healthcare Conference, please visit the Jefferies conference website .
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.
TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.
To learn more about TFF Pharmaceuticals and its product candidates, visit the Companys website at https://tffpharma.com .

TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

Retrieved on:

Friday, November 5, 2021

Investor, NASDAQ, Solubility, Annual report, TFF, Company, Calendar, GLOBE, Absorption, Pharmacokinetics, Webcast, Risk, FDA, Pharmaceutical industry

Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM ET.

Key Points:

Management will host a conference call to discuss the financial results and provide an update on recent corporate and clinical developments at4:30 PM ET.
The Company will host a conference call on Monday, November 15, 2021, at 4:30 PM ET to review the clinical, corporate and financial highlights.
Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
TFF Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

Phunware Acquires Additional Bitcoin

Retrieved on:

Friday, November 5, 2021

Industry, Android, IOS, Security (finance), NASDAQ, 8-K, Social media, Phunware, Advertising, Mobility as a service, IOS SDK, U.S. Securities and Exchange Commission, GLOBE, Solution, SEC, Nature, Cryptocurrency, Public relations

AUSTIN, Texas, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Phunware, Inc. (NASDAQ: PHUN) (the Company), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, announced today it has purchased an additional 100 bitcoin for approximately $6.20 million in cash at an average price of approximately $62,030 per bitcoin, inclusive of fees and expenses.

Key Points:

AUSTIN, Texas, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Phunware, Inc. (NASDAQ: PHUN) (the Company), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, announced today it has purchased an additional 100 bitcoin for approximately $6.20 million in cash at an average price of approximately $62,030 per bitcoin, inclusive of fees and expenses.
As of November 4, 2021, Phunware holds an aggregate of approximately 127 bitcoin, which were acquired at an aggregate purchase price of approximately $7.75 million and an average purchase price of approximately $61,238 per bitcoin, inclusive of fees and expenses.
Phunware helps the worlds most respected brands create category-defining mobile experiences, with approximately one billion active devices touching its platform each month when operating at scale.
For more information about how Phunware is transforming the way consumers and brands interact with mobile in the virtual and physical worlds, visit https://phunware.com , https://phunwallet.com , https://phuncoin.com , https://phuntoken.com , https://lytetechnology.com/ and follow @phunware, @phuncoin and @phuntoken on all social media platforms.

BigCommerce Announces Third Quarter Financial Results

Retrieved on:

Thursday, November 4, 2021

AUSTIN, Texas, Nov. 04, 2021 (GLOBE NEWSWIRE) -- BigCommerce Holdings, Inc. (“BigCommerce”) (Nasdaq: BIGC), a leading Open SaaS ecommerce platform for fast-growing and established brands, today announced financial results for its third quarter ended September 30, 2021.

Key Points:

Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug Candidate

Retrieved on:

Thursday, November 4, 2021

The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Companys lead drug candidate for the proposed treatment of Alzheimers disease.

Key Points:

The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Companys lead drug candidate for the proposed treatment of Alzheimers disease.
In response to this and similar on-line allegations, the Journal of Neuroscience requested raw data for the article, including images of original, uncropped Western blots.
Having received that data and completed its review, the Journal of Neuroscience states: No evidence of data manipulation was found for Western blot data.
In response to allegations of data manipulation in JNeurosci 2012;32:9773-9784 the Journal requested raw data, including images of original, uncropped Western blots.

Phunware Sets November 2021 Conference Schedule

Retrieved on:

Thursday, November 4, 2021

VaxTele SIP Server SDK, Mobility as a service, Advertising, Phunware, NASDAQ, Social media, Company, IOS, Solution, Android, GLOBE, Online shopping

Investors can also request 1x1 meetings with Company on the event website.

Key Points:

Investors can also request 1x1 meetings with Company on the event website.
For additional information or to schedule a one-on-one meeting with Phunware management, please contact Gateway Investor Relations at [email protected].
Phunware helps the worlds most respected brands create category-defining mobile experiences, with approximately one billion active devices touching its platform each month when operating at scale.
For more information about how Phunware is transforming the way consumers and brands interact with mobile in the virtual and physical worlds, visit https://phunware.com , https://phunwallet.com , https://phuncoin.com , https://phuntoken.com , and follow @phunware, @phuncoin and @phuntoken on all social media platforms.

AYRO to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update

Retrieved on:

Thursday, November 4, 2021

Solution, Nasdaq, Organization, Research, CFO, Technology, GLOBE, CEO, Call, Animal, Mobile phone

AUSTIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AYRO, Inc. (Nasdaq: AYRO) (“AYRO” or the “Company”), a designer and manufacturer of electric, purpose-built delivery vehicles and solutions for micro distribution, micro mobility, and last-mile delivery, announces that it will report third quarter 2021 financial results on Thursday, November 11, 2021 before the market open.

Key Points:

Tom Wittenschlaeger, CEO and Curt Smith, CFO will also host a conference call at 8:30 a.m.
ET on Thursday, November 11, 2021, to review financial results and provide an update on corporate developments.
A telephonic replay will be available until November 25, 2021, by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10161908.
Texas-based AYRO, Inc. designs and produces all-electric, purpose-built vehicles that are powered by technology and usable by anyone.